FARMINGTON, Utah / Aug 06, 2024 / Business Wire / PACS Group, Inc. (NYSE: PACS) (“PACS Group” or the “Company”), today announced that it will release its second quarter 2024 financial results after market close on Monday, August 12, 2024. Management will host a call on Monday, August 12, 2024, at 5:00 p.m. Eastern Time to discuss the financial results and related information.
PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://IR.pacs.com, or https://event.choruscall.com/mediaframe/webcast.html?webcastid=k7WXkcZL, or by dialing 877-407-0621 / +1 215-268-9899. A recording of the call will be available for replay via the website for 30 days following the call. The Company’s press releases, SEC filings, public conference calls, webcasts and website frequently disclose information that may be material to investors, and the Company encourages investors and others interested in the Company to regularly monitor those outlets for important Company information.
About PACS Group
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 240 post-acute care facilities across 13 states serving over 25,000 patients daily.
Last Trade: | US$13.20 |
Daily Change: | -0.06 -0.45 |
Daily Volume: | 478,036 |
Market Cap: | US$2.050B |
November 06, 2024 November 01, 2024 September 10, 2024 September 09, 2024 September 03, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load